Bristol Eyes 2008 NDA For DPP-4 Inhibitor Saxagliptin
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm also brokers licensing agreement with Otsuka for the diabetes candidate in Japan.
You may also be interested in...
Bristol-Myers Squibb Targets Mid-year Filing For Saxagliptin
Bristol and AstraZeneca reveal Onglyza brand name, positive monotherapy data for the DPP-4 inhibitor at American Diabetes Association meeting.
Bristol-Myers Squibb Targets Mid-year Filing For Saxagliptin
Bristol and AstraZeneca reveal Onglyza brand name, positive monotherapy data for the DPP-4 inhibitor at American Diabetes Association meeting.
Industry Eyes DPP-4, GLP-1 Data From Diabetes Meeting
BMS to release first Phase III data on saxagliptin as monotherapy.